Orilanolimab(Syntimmune, Inc.) is a Monoclonal antibody targeting FcRn, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks.

Riliprubart is a Monoclonal antibody targeting C1S, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Fidanacogene elaparvovec: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Ralinepag is a Small molecule drug targeting PGI2 receptor, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Verdiperstat is a Small molecule drug targeting MPO, at Phase 1. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Nomacopan is a Recombinant protein targeting C5, at Preclinical. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Narsoplimab is a Monoclonal antibody targeting MASP2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Cinpanemab: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Fitusiran is a siRNA targeting AT III, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Dazodalibep is a Fusion protein targeting CD40L, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Teprotumumab-TRBW is a Monoclonal antibody targeting IGF-1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Cariprazine hydrochloride is a Small molecule drug targeting 5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor, at Approved. This 2026 report.